Bioventus walked into this Q3 2026 report with a stock already under pressure, and it just took another hit. Shares closed at US$13.15 before the release and then slumped about 17% to roughly US$10.95 as investors reacted in real time. The headline result looked steadier than the price suggests. Management kept full year adjusted earnings per share guidance unchanged, while adjusted EBITDA margin held at a firm 20%. The issue was on the top line, as full year revenue guidance moved lower...
Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.
Bioventus benefits from improved financing flexibility, with a term loan maturity extended to 2030 and a 75 bps interest margin reduction. See why BVS is a Buy.
Here is how Bioventus (BVS) and Amneal Pharmaceuticals (AMRX) have performed compared to their sector so far this year.
This is the newest page. Registered accounts read further back.